Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Large B Cell Lymphoma: early-phase trial registry
53 of 115 indexed Diffuse Large B Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #110 of 28,707 conditions by registered trial count.
115 US clinical trials · 53 currently recruiting · #110 of 28,707 conditions by registered trial count
Diffuse Large B Cell Lymphoma: 115 US clinical trials tracked, 53 recruiting.
Diffuse Large B Cell Lymphoma is the subject of 115 registered US clinical trials on ClinicalTrials.gov, 53 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most active sponsor is Genmab, running 6 of these trials.
Enrollment posture brief
Registry condition diffuse-large-b-cell-lymphoma
OPEN 53 | RECR 46% | LATE 11 | EARLY 88 | RANK #110 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Recurrent Glioblastoma (46% recruiting · 63 trials)
Diffuse Large B Cell Lymphoma lists 53 open slots (46% of 115 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Large B Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Large B Cell Lymphoma is recruiting above its size-band peers.
53 of 115 indexed trials (46.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diffuse Large B Cell Lymphoma trials is spread across many organizations.
Genmab accounts for 6 of 115 trials (5.2%). 77 distinct sponsors appear on at least one study for this condition label.
-
Most Diffuse Large B Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 115 trials that report a genuine target (sentinel values excluded). 72 of those (62.6%) plan for fewer than 100 participants.
-
Diffuse Large B Cell Lymphoma research is mostly interventional.
107 interventional and 8 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
115 total, page 2 of 3
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
University of Utah
NCT06227026
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
NCT06977711
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Yale University
NCT06898905
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT03274492
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab
NCT05578976
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Incyte Corporation
NCT04824092
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Acerta Pharma
NCT04529772
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Mayo Clinic
NCT01787409
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Genmab
NCT04663347
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab
NCT04628494
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
NCT03984448
Communication Skills Intervention to Promote Transition Into Survivorship
Memorial Sloan Kettering Cancer Center
NCT01483664
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT04408638
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
Duke University
NCT03681535
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Seagen, a wholly owned subsidiary of Pfizer
NCT04404283
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis Pharmaceuticals
NCT03960840
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT03162536
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Genmab
NCT05451810
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Genmab
NCT05660967
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
NCT03656835
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05565417
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Molly Gallogly
NCT03064867
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
NCT04978584
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Incyte Corporation
NCT05222555
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
NCT03995147
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
NCT04323956
Copanlisib Plus Venetoclax in R/R DLBCL
Dana-Farber Cancer Institute
NCT04572763
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT03842696
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT03147885
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
NCT05665062
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
NCT04464200
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
David Bond, MD
NCT03749018
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
NCT03943901
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03884998
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
Pfizer
NCT05896163
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Patrick Reagan
NCT02734771
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Tessa Therapeutics
NCT04526834
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Catherine Bollard
NCT03843294
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT04479267
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT06870487
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT05498220
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
Novartis Pharmaceuticals
NCT05918809
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT04182204
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT01177397
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT03677154
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
AstraZeneca
NCT01499303
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03833180
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
NCT02362997
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
Duke University
NCT01186978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 30 |
| Phase 3 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Large B Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Large B Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Large B Cell Lymphoma page
115 registered trials, 53 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 53 Diffuse Large B Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genmab sponsors the most Diffuse Large B Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Genmab's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Large B Cell Lymphoma condition card totals 115 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.